FLT3 and precursor B-cell acute lymphoblastic leukemia: Given the current uncertainty regarding the prognostic value of FLT3 alterations in pediatric B-ALL and considering recent reports of the therapeutic efficacy of FLT3 inhibitors in patients with relapsed B-cell ALL (46–48), it is essential to deepen our understanding in this field of research.